For procurement managers and R&D scientists in the pharmaceutical and biotechnology sectors, sourcing high-quality Active Pharmaceutical Ingredients (APIs) and intermediates is a critical undertaking. ABT-199 (CAS 1257044-40-8), a selective Bcl-2 inhibitor, is a compound of immense interest due to its therapeutic potential in treating various cancers, particularly chronic lymphocytic leukemia (CLL).

When looking to purchase ABT-199, understanding its key attributes is essential. Purity, consistent batch-to-batch quality, and comprehensive analytical data (such as Certificates of Analysis, HPLC, and MS data) are non-negotiable. These factors directly impact the reliability and success of research experiments and the development of pharmaceutical products. Therefore, identifying a trusted manufacturer or supplier for ABT-199 is paramount.

China has emerged as a significant hub for the production of pharmaceutical intermediates and APIs, offering competitive pricing without compromising on quality. Buyers seeking ABT-199 should look for manufacturers who adhere to international quality standards and possess robust production capabilities. Features like the ability to supply in various quantities, from research-scale grams to bulk kilograms for clinical trials, are important indicators of a reliable supplier.

When you inquire about ABT-199, pay attention to the supplier's responsiveness, technical support, and logistics. A responsive manufacturer will provide prompt quotes, detailed product information, and efficient shipping solutions, ensuring your procurement process is seamless. Understanding the molecular formula (C45H50ClN7O7S) and molecular weight (868.44) of ABT-199, along with its physical appearance (Yellow Solid), are fundamental pieces of information to verify product authenticity and quality.

Furthermore, engaging with suppliers who can provide information on its application in treating Bcl-2 dependent cancers or as a tool in apoptosis research adds value. By carefully vetting suppliers and understanding the critical specifications of ABT-199, procurement professionals can ensure they are obtaining a high-quality pharmaceutical intermediate that will support their critical drug development pipelines. Exploring options from established manufacturers in China can provide both cost-efficiency and a stable supply chain for this vital compound.